Entrada Therapeutics, Inc. (TRDA)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Dipal Doshi
|
CEO & Director | 998.25k | -- | 1976 |
|
Mr. Nathan J. Dowden
|
President & COO | 737.18k | -- | 1971 |
|
Dr. Natarajan Sethuraman Ph.D.
|
President of Research & Development | 768k | -- | 1962 |
|
Mr. Kory James Wentworth CPA
|
CFO & Treasurer | -- | -- | 1979 |
|
Dr. Jared Cohen J.D., Ph.D.
|
General Counsel | -- | -- | -- |
Entrada Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 152
Description
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
Entrada Therapeutics, Inc. Earnings Date
Recent Events
December 1, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
